Palvella Therapeutics, Inc. (PVLA)
146.15
-5.43
(-3.58%)
USD |
NASDAQ |
Oct 30, 16:00
145.98
-0.17
(-0.12%)
After-Hours: 20:00
Palvella Therapeutics Enterprise Value : 1.876B for Oct. 30, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 30, 2026 | 1.876B |
| October 29, 2026 | 1.954B |
| October 28, 2026 | 1.895B |
| October 27, 2026 | 1.685B |
| October 26, 2026 | 1.589B |
| October 23, 2026 | 1.573B |
| October 22, 2026 | 1.592B |
| October 21, 2026 | 1.594B |
| October 20, 2026 | 1.556B |
| October 19, 2026 | 1.542B |
| October 16, 2026 | 1.504B |
| October 15, 2026 | 1.605B |
| October 14, 2026 | 1.537B |
| October 13, 2026 | 1.622B |
| October 12, 2026 | 1.707B |
| October 09, 2026 | 1.770B |
| October 08, 2026 | 1.663B |
| October 07, 2026 | 1.652B |
| October 06, 2026 | 1.615B |
| October 05, 2026 | 1.675B |
| October 02, 2026 | 1.679B |
| October 01, 2026 | 1.683B |
| September 30, 2026 | 1.758B |
| September 29, 2026 | 1.773B |
| September 28, 2026 | 1.785B |
| Date | Value |
|---|---|
| September 25, 2026 | 1.761B |
| September 24, 2026 | 1.875B |
| September 23, 2026 | 1.925B |
| September 22, 2026 | 2.048B |
| September 21, 2026 | 1.981B |
| September 18, 2026 | 1.939B |
| September 17, 2026 | 1.994B |
| September 16, 2026 | 1.952B |
| September 15, 2026 | 1.949B |
| September 14, 2026 | 1.956B |
| September 11, 2026 | 1.933B |
| September 10, 2026 | 1.937B |
| September 09, 2026 | 1.951B |
| September 08, 2026 | 1.964B |
| September 04, 2026 | 2.036B |
| September 03, 2026 | 2.010B |
| September 02, 2026 | 1.974B |
| September 01, 2026 | 1.939B |
| August 31, 2026 | 1.969B |
| August 28, 2026 | 1.931B |
| August 27, 2026 | 1.936B |
| August 26, 2026 | 1.994B |
| August 25, 2026 | 1.906B |
| August 24, 2026 | 1.870B |
| August 21, 2026 | 1.817B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Arcus Biosciences, Inc. | 1.722B |
| Design Therapeutics, Inc. | 463.62M |
| Agenus, Inc. | 556.15M |
| Amgen, Inc. | 295.24B |
| Anika Therapeutics, Inc. | 267.21M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -21.87M |
| Total Expenses (Quarterly) | 21.87M |
| EPS Diluted (Quarterly) | -1.523 |
| Earnings Yield | -3.31% |
| Normalized Earnings Yield | -3.290 |